

# Clinical trials of cilostazol

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 stent

Trial	Treatments	Patients	Trials design and methods
<b>cilostazol vs aspirin</b>			
<a href="#">Kunishima , 1997</a> n=30/40	Cilostazol 200 mg qD unspecified durationg qD versus Aspirin 81 mg qD	-	
<b>cilostazol + aspirin vs aspirin</b>			
<a href="#">Sekiya , 1998</a> n=63/63	Cilostazol 200 mg qD x6mos Aspirin 81 mg qD versus Coumadin unspecified regimen Aspirin 81 mg qD	-	
<b>cilostazol + aspirin vs ticlopidine + aspirin</b>			
<a href="#">Kozuma , 2001</a> n=62/63	Cilostazol 200 mg qD x6 mos Aspirin 81162 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81162 mg qD	-	
<a href="#">Ochiai , 1999</a> n=25/25	Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID versus Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID	-	
<a href="#">Park , 1999</a> n=247/243	Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD	-	
<a href="#">Yoon , 1999</a> n=147/149	Cilostazol 100 mg BID x30 days Aspirin 100 mg qD versus Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD	-	

continued...

Trial	Treatments	Patients	Trials design and methods
Kamishirado , 2002 n=65/65	Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD	-	

More details and results :

- antithrombotics for stent in all type of patients at <http://www.trialresultscenter.org/go-Q151>

## References

### Kunishima, 1997:

Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, So T, Nakamura T, Oohama N, Murayama M A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997;19:1058-66 [9385493]

### Sekiya, 1998:

Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 1998;82:144-7 [9678282]

### Kozuma, 2001:

Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, Tanabe K, Ikari Y, Tamura T Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J 2001;141:124-30 [11136497]

### Ochiai, 1999:

Ochiai M, Eto K, Takeshita S, Yokoyama N, Oshima A, Kondo K, Sato T, Isshiki T Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. Am J Cardiol 1999;84:1074-6, A6, A9 [10569666]

### Park, 1999:

Park SW, Lee CW, Kim HS, Lee HJ, Park HK, Hong MK, Kim JJ, Park SJ Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999;84:511-4 [10482146]

### Yoon, 1999:

Yoon Y, Shim WH, Lee DH, Pyun WB, Kim IJ, Jang Y, Cho SY Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999;84:1375-80 [10606107]

### Kamishirado, 2002:

Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, Takayanagi K, Morooka S Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 2002;144:303-8 [12177649]

## 2 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
<b>cilostazol vs placebo</b>			
Elam , 1998 n=NA follow-up:	cilostazol 100 mg twice daily versus placebo	-	Parallel groups double blind US
Otsuka 21-95-201 n=NA follow-up: 12 weeks	-	-	Parallel groups double blind US
Dawson , 1998 n=54/27 follow-up: 3 mois	Cilostazol 200 mg/d versus placebo	Stade de la maladie: II, avec dure des symptomes (annes) de : 6.25+/-0.82	Parallel groups Double aveugle
Beebe , 1999 n=346/170 follow-up: 6 mois	Cilostazol 100 ou 200 mg / j (2 groupes) versus placebo	AOMI stade II	Parallel groups Double aveugle
Dawson (cilostazol) , 2000 n=227/239 follow-up: 6 mois	Cilostazol 200 mg/d versus placebo	Stade de la maladie: II en situation chronique.	Parallel groups Double aveugle
Money , 1998 n=119/120 follow-up: 4 mois	Cilostazol 200 mg/d versus placebo	Stade de la maladie: II	Parallel groups Double aveugle
Strandness , 2002 n=265/129 follow-up: 6 mois	cilostazol 50 or 100 mg twice daily versus placebo	AOMI stade II.	Parallel groups Double aveugle

More details and results :

- vasodilators therapy for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q49>

## References

### Elam, 1998:

Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. *Arterioscler Thromb Vasc Biol* 1998;18:1942-7 [9848888]

### Otsuka 21-95-201, :

### Dawson, 1998:

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr *Circulation* 1998 Aug 18;98:678-86 [9715861]

### Beebe, 1999:

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, Forbes WP Arch Intern Med 1999 Sep 27;159:2041-50 [[10510990](#)]

**Dawson (cilostazol), 2000:**

Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, Forbes WP, Strandness DE Jr. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000 Nov;109:523-30.

**Money, 1998:**

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP J Vasc Surg 1998 Feb;27:267-74; discussion 274-5 [[9510281](#)]

**Strandness, 2002:**

Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, Forbes WP. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg 2002 Mar-Apr;36:83-91.

### 3 percutaneous coronary intervention

4

Trial	Treatments	Patients	Trials design and methods
<b>cilostazol vs aspirin</b>			
<a href="#">Kunishima , 1997</a> n=30/40	Cilostazol 200 mg qD unspecified duration qD versus Aspirin 81 mg qD	-	
<b>cilostazol + aspirin vs aspirin</b>			
<a href="#">Sekiya , 1998</a> n=63/63	Cilostazol 200 mg qD x6mos Aspirin 81 mg qD versus Coumadin unspecified regimen Aspirin 81 mg qD	-	
<b>cilostazol + aspirin vs ticlopidine + aspirin</b>			
<a href="#">Kozuma , 2001</a> n=62/63	Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD	-	
<a href="#">Ochiai , 1999</a> n=25/25	Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID versus Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID	-	

continued...

Trial	Treatments	Patients	Trials design and methods
Park , 1999 n=247/243	Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD	-	
Yoon , 1999 n=147/149	Cilostazol 100 mg BID x30 days Aspirin 100 mg qD versus Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD	-	
Kamishirado , 2002 n=65/65	Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD	81 -	

More details and results :

- antithrombotics for percutaneous coronary intervention in PCI with stent placement at <http://www.trialresultscenter.org/go-Q152>
- antiplatelets drug for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q389>

## References

### Kunishima, 1997:

Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, So T, Nakamura T, Oohama N, Murayama M A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997;19:1058-66 [9385493]

### Sekiya, 1998:

Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 1998;82:144-7 [9678282]

### Kozuma, 2001:

Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, Tanabe K, Ikari Y, Tamura T Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J 2001;141:124-30 [11136497]

### Ochiai, 1999:

Ochiai M, Eto K, Takeshita S, Yokoyama N, Oshima A, Kondo K, Sato T, Isshiki T Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. Am J Cardiol 1999;84:1074-6, A6, A9 [10569666]

### Park, 1999:

Park SW, Lee CW, Kim HS, Lee HJ, Park HK, Hong MK, Kim JJ, Park SJ Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999;84:511-4 [10482146]

**Yoon, 1999:**

Yoon Y, Shim WH, Lee DH, Pyun WB, Kim IJ, Jang Y, Cho SY Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999;84:1375-80 [10606107]

**Kamishirado, 2002:**

Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, Takayanagi K, Morooka S Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 2002;144:303-8 [12177649]

Entry terms: clopidogrel, Plavix, Iscover